HIV Clinical Trials

The purpose of the study is to see if there is a relationship to exposure to violence and HIV risk behaviors in young men who engage in same sex relationships. This is a one-time survey. Participation will take about 30 minutes. Participants may be asked if they are willing to ...

The primary objective of the study is to evaluate the longterm effect of EGRIFTA®, 2 mg once daily subcutaneously (SC), on the development of malignancies in subjects with human immunodeficiency virus (HIV) infection and concomitant abdominal lipohypertrophy. ClinicalTrials.gov Identifier: NCT01579695

GPS is a sexual health promotion and HIV prevention peer-delivered counselling program. The GPS program has 4 parts: information provision about HIV and sexually transmitted infections, motivational interviewing counselling, sexual health behavioural skills building, and linkage to care. The adaptation grant has three goals: 1) to establish a multi-region and ...

Researchers at the University of Kentucky are conducting a study to learn how two different medications that are used to treat opioid use disorder affect the health of patients who are HIV-positive. We will be learning about a drug called Extended-Release Naltrexone. We hope to find out if using the ...

This randomized phase III trial compares topical or ablative treatment with active monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and high-grade squamous intraepithelial lesions (HSIL). Anal HSIL is tissue in the anal canal that has been damaged by infection with human papillomavirus (HPV) and is ...

The primary objective of this study is to evaluate the efficacy of fixed-dose combination (FDC) of bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + emtricitabine/tenofovir disoproxil fumarate (F/TDF) in HIV and hepatitis B virus (HBV) treatment naive, HIV-1 and HBV co-infected adults.  

There will be 2 study visits (about 6 hours total). There will be memory tests and MRI scan. Up to $250 is provided for time and effort. Risks and benefits will be discussed as part of the informed consent process (IRB # 201805047).  

A four-site intradermal rabies booster vaccination has shown higher immune response than conventional intramuscular rabies booster vaccination in healthy persons. So, the investigators hypothesized the same outcome in HIV - infected patients.

We propose a factorial design strategy to evaluate the effects, individually and in combination, of the most promising pharmaco- and behavioral cessation therapies available for PLWH according to our review of the extant literature for HIV-infected and general population smokers. The sizable cohort and prospective design will also permit us ...

From 2000-2010, the annual number of new HIV diagnoses among MSM aged 13-24 years old more than doubled. There are stark racial and ethnic disparities in the incidence of new HIV infections among YMSM; 13- 24 year old racial and ethnic minority MSM now represent a rapidly growing share of ...